What's Happening?
An international multidisciplinary panel of experts has published a new consensus in Gastroenterology in 2026, providing a framework for recognizing and managing irritable bowel syndrome (IBS)-like symptoms in patients with inflammatory bowel disease
(IBD) who are in remission. Approximately one in four IBD patients continue to experience symptoms such as abdominal pain, bloating, and altered bowel habits even when their intestinal inflammation is controlled. The consensus recommends using the term 'IBD with IBS-like symptoms' for these cases, emphasizing that these symptoms are not explained by active inflammation or structural disease. The approach involves a structured diagnosis combining Rome clinical criteria with objective assessment of inflammatory activity, ensuring that IBD treatment is optimized if inflammation is present, and addressing IBS-like symptoms if inflammation is absent. Treatment options include psyllium, a short-term low-FODMAP diet (4 to 8 weeks) with reintroduction and personalization, symptom-targeted pharmacological treatments, and brain–gut behavioral therapies.
Why It's Important?
This new consensus is critical for improving the quality of life for a significant portion of IBD patients in the U.S. who suffer from persistent IBS-like symptoms despite being in remission. Previously, the lack of a clear framework often led to either unnecessary escalation of IBD treatment or inadequate management of symptoms, leaving patients in discomfort. By distinguishing between inflammatory remission and symptom resolution, the consensus ensures that treatment is appropriately targeted, preventing potential overtreatment of IBD and providing effective relief for IBS-like symptoms. This individualized approach, incorporating dietary interventions and behavioral therapies, acknowledges the complex mechanisms underlying these symptoms, including altered motility, visceral hypersensitivity, and gut-brain communication issues. It also highlights the importance of dietetic support, especially for nutritionally vulnerable IBD patients, and the role of mental health interventions in managing chronic conditions.
What's Next?
Clinicians are encouraged to adopt the new terminology and diagnostic framework to better evaluate and manage IBD patients with persistent IBS-like symptoms. This involves a careful assessment to determine if symptoms are driven by inflammation or other mechanisms. The implementation of short-term low-FODMAP diets, guided by dietitians, and the integration of brain–gut behavioral therapies are expected to become more common. Challenges remain in ensuring equitable access to dietitians and clinicians trained in these specialized therapies. Future research will focus on developing better disease-specific measures, conducting larger controlled trials, and exploring the potential role of gut microbiome profiling in distinguishing active IBD from IBS-like symptoms, though the latter is not yet a validated diagnostic tool for current clinical practice.
Beyond the Headlines
The consensus sheds light on the intricate relationship between physical disease and functional symptoms, challenging the traditional medical model that often separates the two. It underscores the concept of the gut-brain axis, recognizing that psychological factors and neural pathways play a significant role in digestive health, even in the absence of active inflammation. This integrated approach has broader implications for chronic disease management, advocating for personalized care that considers the patient's overall well-being, including their nutritional status and psychological burden. The need for specialized dietetic and behavioral therapy support also highlights gaps in healthcare infrastructure and training, suggesting a need for greater investment in these areas to provide comprehensive care for complex conditions like IBD. This shift towards a more holistic understanding of patient symptoms could pave the way for more effective and compassionate healthcare delivery.
